DANONE (BSN.DE) Fundamental Analysis & Valuation

FRA:BSN • FR0000120644

70.02 EUR
-0.94 (-1.32%)
Last: Mar 5, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership

This BSN.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

BSN gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 61 industry peers in the Food Products industry. BSN scores excellent on profitability, but there are concerns on its financial health. BSN has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

7

1. BSN.DE Profitability Analysis

1.1 Basic Checks

  • In the past year BSN was profitable.
  • BSN had a positive operating cash flow in the past year.
  • Each year in the past 5 years BSN has been profitable.
  • In the past 5 years BSN always reported a positive cash flow from operatings.
BSN.DE Yearly Net Income VS EBIT VS OCF VS FCFBSN.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1B 2B 3B

1.2 Ratios

  • With a decent Return On Assets value of 4.03%, BSN is doing good in the industry, outperforming 65.57% of the companies in the same industry.
  • The Return On Equity of BSN (10.74%) is better than 63.93% of its industry peers.
  • The Return On Invested Capital of BSN (8.41%) is better than 75.41% of its industry peers.
  • The Average Return On Invested Capital over the past 3 years for BSN is in line with the industry average of 6.64%.
  • The 3 year average ROIC (7.72%) for BSN is below the current ROIC(8.41%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 4.03%
ROE 10.74%
ROIC 8.41%
ROA(3y)3.48%
ROA(5y)3.34%
ROE(3y)9.16%
ROE(5y)8.75%
ROIC(3y)7.72%
ROIC(5y)7.34%
BSN.DE Yearly ROA, ROE, ROICBSN.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5 10 15

1.3 Margins

  • With a decent Profit Margin value of 6.66%, BSN is doing good in the industry, outperforming 72.13% of the companies in the same industry.
  • BSN's Profit Margin has declined in the last couple of years.
  • BSN has a better Operating Margin (13.43%) than 83.61% of its industry peers.
  • BSN's Operating Margin has been stable in the last couple of years.
  • The Gross Margin of BSN (50.62%) is better than 85.25% of its industry peers.
  • In the last couple of years the Gross Margin of BSN has remained more or less at the same level.
Industry RankSector Rank
OM 13.43%
PM (TTM) 6.66%
GM 50.62%
OM growth 3Y3.18%
OM growth 5Y-0.95%
PM growth 3Y24.92%
PM growth 5Y-4.12%
GM growth 3Y3.2%
GM growth 5Y1.04%
BSN.DE Yearly Profit, Operating, Gross MarginsBSN.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. BSN.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so BSN is still creating some value.
  • BSN has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, BSN has less shares outstanding
  • Compared to 1 year ago, BSN has a worse debt to assets ratio.
BSN.DE Yearly Shares OutstandingBSN.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M
BSN.DE Yearly Total Debt VS Total AssetsBSN.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.2 Solvency

  • BSN has an Altman-Z score of 2.43. This is not the best score and indicates that BSN is in the grey zone with still only limited risk for bankruptcy at the moment.
  • BSN's Altman-Z score of 2.43 is fine compared to the rest of the industry. BSN outperforms 60.66% of its industry peers.
  • The Debt to FCF ratio of BSN is 5.29, which is a neutral value as it means it would take BSN, 5.29 years of fcf income to pay off all of its debts.
  • BSN has a better Debt to FCF ratio (5.29) than 68.85% of its industry peers.
  • A Debt/Equity ratio of 0.58 indicates that BSN is somewhat dependend on debt financing.
  • BSN has a Debt to Equity ratio of 0.58. This is comparable to the rest of the industry: BSN outperforms 49.18% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF 5.29
Altman-Z 2.43
ROIC/WACC1.3
WACC6.48%
BSN.DE Yearly LT Debt VS Equity VS FCFBSN.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 0.90 indicates that BSN may have some problems paying its short term obligations.
  • BSN's Current ratio of 0.90 is on the low side compared to the rest of the industry. BSN is outperformed by 77.05% of its industry peers.
  • BSN has a Quick Ratio of 0.90. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
  • BSN's Quick ratio of 0.75 is in line compared to the rest of the industry. BSN outperforms 40.98% of its industry peers.
Industry RankSector Rank
Current Ratio 0.9
Quick Ratio 0.75
BSN.DE Yearly Current Assets VS Current LiabilitesBSN.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. BSN.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 2.54% over the past year.
  • The Earnings Per Share has been decreasing by -1.17% on average over the past years.
  • The Revenue has decreased by -0.34% in the past year.
  • The Revenue has been growing slightly by 1.60% on average over the past years.
EPS 1Y (TTM)2.54%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%-3.3%
Revenue 1Y (TTM)-0.34%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.54%

3.2 Future

  • BSN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.97% yearly.
  • The Revenue is expected to grow by 3.07% on average over the next years.
EPS Next Y7.53%
EPS Next 2Y7.18%
EPS Next 3Y7.53%
EPS Next 5Y6.97%
Revenue Next Year0.34%
Revenue Next 2Y1.63%
Revenue Next 3Y2.39%
Revenue Next 5Y3.07%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BSN.DE Yearly Revenue VS EstimatesBSN.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 10B 20B 30B
BSN.DE Yearly EPS VS EstimatesBSN.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1 2 3 4 5

More info and screens

Find the best growth stocksShow best growing peers

4

4. BSN.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • BSN is valuated rather expensively with a Price/Earnings ratio of 19.29.
  • The rest of the industry has a similar Price/Earnings ratio as BSN.
  • BSN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.69.
  • BSN is valuated correctly with a Price/Forward Earnings ratio of 16.79.
  • The rest of the industry has a similar Price/Forward Earnings ratio as BSN.
  • BSN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 24.79, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 19.29
Fwd PE 16.79
BSN.DE Price Earnings VS Forward Price EarningsBSN.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • BSN's Enterprise Value to EBITDA ratio is in line with the industry average.
  • 62.30% of the companies in the same industry are more expensive than BSN, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 17.51
EV/EBITDA 10.15
BSN.DE Per share dataBSN.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates BSN does not grow enough to justify the current Price/Earnings ratio.
  • BSN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.56
PEG (5Y)N/A
EPS Next 2Y7.18%
EPS Next 3Y7.53%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. BSN.DE Dividend Analysis

5.1 Amount

  • BSN has a Yearly Dividend Yield of 3.09%.
  • Compared to an average industry Dividend Yield of 2.47, BSN pays a bit more dividend than its industry peers.
  • Compared to an average S&P500 Dividend Yield of 1.82, BSN pays a better dividend.
Industry RankSector Rank
Dividend Yield 3.09%

5.2 History

  • The dividend of BSN has a limited annual growth rate of 0.37%.
Dividend Growth(5Y)0.37%
Div Incr Years3
Div Non Decr Years4
BSN.DE Yearly Dividends per shareBSN.DE Yearly Dividends per shareYearly Dividends per share 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3 4

5.3 Sustainability

  • BSN pays out 75.89% of its income as dividend. This is not a sustainable payout ratio.
  • The dividend of BSN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP75.89%
EPS Next 2Y7.18%
EPS Next 3Y7.53%
BSN.DE Yearly Income VS Free CF VS DividendBSN.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B
BSN.DE Dividend Payout.BSN.DE Dividend Payout, showing the Payout Ratio.BSN.DE Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

BSN.DE Fundamentals: All Metrics, Ratios and Statistics

DANONE

FRA:BSN (3/5/2026, 7:00:00 PM)

70.02

-0.94 (-1.32%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)02-20
Earnings (Next)04-22
Inst Owners54.21%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap47.71B
Revenue(TTM)27.28B
Net Income(TTM)1.82B
Analysts75.63
Price Target80.77 (15.35%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 3.09%
Yearly Dividend2.14
Dividend Growth(5Y)0.37%
DP75.89%
Div Incr Years3
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.39%
PT rev (3m)-0.15%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-0.31%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.48%
Revenue NY rev (3m)-0.44%
Valuation
Industry RankSector Rank
PE 19.29
Fwd PE 16.79
P/S 1.75
P/FCF 17.51
P/OCF 12.62
P/B 2.82
P/tB N/A
EV/EBITDA 10.15
EPS(TTM)3.63
EY5.18%
EPS(NY)4.17
Fwd EY5.95%
FCF(TTM)4
FCFY5.71%
OCF(TTM)5.55
OCFY7.92%
SpS40.04
BVpS24.83
TBVpS-9.13
PEG (NY)2.56
PEG (5Y)N/A
Graham Number45.03
Profitability
Industry RankSector Rank
ROA 4.03%
ROE 10.74%
ROCE 12.04%
ROIC 8.41%
ROICexc 10.73%
ROICexgc 346.67%
OM 13.43%
PM (TTM) 6.66%
GM 50.62%
FCFM 9.99%
ROA(3y)3.48%
ROA(5y)3.34%
ROE(3y)9.16%
ROE(5y)8.75%
ROIC(3y)7.72%
ROIC(5y)7.34%
ROICexc(3y)9.59%
ROICexc(5y)8.95%
ROICexgc(3y)160.19%
ROICexgc(5y)113.94%
ROCE(3y)11.59%
ROCE(5y)10.94%
ROICexgc growth 3Y98.63%
ROICexgc growth 5Y58.06%
ROICexc growth 3Y10.31%
ROICexc growth 5Y6.47%
OM growth 3Y3.18%
OM growth 5Y-0.95%
PM growth 3Y24.92%
PM growth 5Y-4.12%
GM growth 3Y3.2%
GM growth 5Y1.04%
F-Score7
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 0.58
Debt/FCF 5.29
Debt/EBITDA 1.94
Cap/Depr 77.86%
Cap/Sales 3.87%
Interest Coverage 21.06
Cash Conversion 75.3%
Profit Quality 149.97%
Current Ratio 0.9
Quick Ratio 0.75
Altman-Z 2.43
F-Score7
WACC6.48%
ROIC/WACC1.3
Cap/Depr(3y)69.82%
Cap/Depr(5y)67.75%
Cap/Sales(3y)3.44%
Cap/Sales(5y)3.55%
Profit Quality(3y)197.13%
Profit Quality(5y)188.13%
High Growth Momentum
Growth
EPS 1Y (TTM)2.54%
EPS 3Y3.12%
EPS 5Y-1.17%
EPS Q2Q%-3.3%
EPS Next Y7.53%
EPS Next 2Y7.18%
EPS Next 3Y7.53%
EPS Next 5Y6.97%
Revenue 1Y (TTM)-0.34%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%-0.54%
Revenue Next Year0.34%
Revenue Next 2Y1.63%
Revenue Next 3Y2.39%
Revenue Next 5Y3.07%
EBIT growth 1Y3.01%
EBIT growth 3Y2.7%
EBIT growth 5Y1.95%
EBIT Next Year37.05%
EBIT Next 3Y14.76%
EBIT Next 5Y10.74%
FCF growth 1Y-6.26%
FCF growth 3Y9.25%
FCF growth 5Y6.33%
OCF growth 1Y-1.31%
OCF growth 3Y8.46%
OCF growth 5Y4.96%

DANONE / BSN.DE FAQ

What is the fundamental rating for BSN stock?

ChartMill assigns a fundamental rating of 5 / 10 to BSN.DE.


What is the valuation status for BSN stock?

ChartMill assigns a valuation rating of 3 / 10 to DANONE (BSN.DE). This can be considered as Overvalued.


How profitable is DANONE (BSN.DE) stock?

DANONE (BSN.DE) has a profitability rating of 7 / 10.


What is the earnings growth outlook for DANONE?

The Earnings per Share (EPS) of DANONE (BSN.DE) is expected to grow by 7.53% in the next year.


Is the dividend of DANONE sustainable?

The dividend rating of DANONE (BSN.DE) is 6 / 10 and the dividend payout ratio is 75.89%.